This Alnylam Pharmaceuticals Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday

Side,View,Of,Concentrated,Crypto,Trader,Sitting,In,Front,Of

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• JP Morgan analyst Kenneth Worthington upgraded Federated Hermes, Inc. (NYSE:FHI) from Underweight to Neutral and raised the price target from $40 to $54. Federated Hermes shares closed at $49.23 on Friday. See how other analysts view this stock.
• Telsey Advisory Group analyst Dana Telsey upgraded Zevia PBC (NYSE:ZVIA) from Market Perform to Outperform and raised the price target from $3 to $5. Zevia shares closed at $3.04 on Friday. See how other analysts view this stock.
• Wolfe Research analyst Andy Chen upgraded the rating for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) from Underperform to Peer Perform. Alnylam Pharmaceuticals shares closed at $401.80 on Friday. See how other analysts view this stock.
• Baird analyst Joseph Grabowski upgraded Alamo Group Inc. (NYSE:ALG) from Neutral to Outperform and boosted the price target from $209 to $260. Alamo Group shares closed at $215.62 on Friday. See how other analysts view this stock.
• Wolfe Research analyst Andrew Rosivach upgraded Apartment Investment and Management Company (NYSE:AIV) from Peer Perform to Outperform and maintained the price target of $10. Procore Technologies shares closed at $8.39 on Friday. See how other analysts view this stock.

Considering buying ALNY stock? Here’s what analysts think:

Read This Next:

• Wall Street’s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

Photo via Shutterstock